LICENSE AGREEMENT AMENDMENT
Exhibit 10.1.4
LICENSE AGREEMENT AMENDMENT
The following is an amendment to Exhibit A of the License Agreement between Medical College of Georgia and NewLink Genetics previously executed on September 13th, 2005. The purpose of this amendment is to explicitly list patent applications filed previously to the execution of this Agreement as continuations of Case # 009-03, and which were unintentionally ommited in the original Exhibit A. These missing patent applications are: Provisional US 60/538,647 and Non-Provisional Patents US 10/780,150 and US 10/780,797.
The present amendment should be considered part of the original License Agreement and is hereto agreed by representatives of both parties signing below.
MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE | LICENSEE: NEWLINK GENETICS | ||||
By: /s/ Xxxxx Xxxxxxxx | By: /s/ Xxxxxxxx Xxxxxxxx | ||||
Name: Xxxxx Xxxxxxxx Executive Director MCG Research Institute | Name: Xxxxxxxx Xxxxxxxx | ||||
Title: | Title: Chief Medical & Operations Officer | ||||
Date: 3/28/06 | Date: 3/28/06 | ||||
EXHIBIT A
LICENSED PATENTS
[Case #007-98 | “Regulation of T-Cell Mediated Immunity by Tryptophan” U.S. Patent No. 6,451,840 Inventors: X. Xxxx and X. Xxxxxx | ||||
Case #007-98 Div1 | “Regulation of T-Cell Mediated Immunity by Tryptophan” U.S. Patent No. 6,482,416 Inventors: X. Xxxx and X. Xxxxxx | ||||
Case #007-98 Div2 | “Regulation of T-Cell Mediated Immunity by Tryptophan” U.S. non-Provisional/Regular Patent Application 10/112,362 Inventors: X. Xxxx and X. Xxxxxx | ||||
Case #011-98 | High Affinity Tryptophan Transporter” U.S. Patent No. 6,395,876 Inventors: X. Xxxx and X. Xxxxxx | ||||
Case #011-02 | “Antigen-Presenting Cell Populations and Their Use as Reagents for Enhancing of Reducing Immune Tolerance” U.S. non-Provisional/Regular Patent Application 10/121,909 Inventors: X. Xxxx and X. Xxxxxx | ||||
Case #003-03 | “Chemokine Receptor Antagonists as Therapeutic Agents” U.S. non-Provisional/Regular Patent Application 10/660,131 Inventors: X. Xxxx, X. Xxxxxx and X. Xxxxxx | ||||
Case #009-03 | “Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase” U.S. Provisional Patent Application 60/459,489 Inventors: X. Xxxx and X. Xxxxxx | ||||
Case #009-03 | “Inhibitors of Indoleamine-2,3-Dioxygenase and Methods of Use” U.S. Provisional Patent Application 60/538,647 Inventors: X. Xxxx and X. Xxxxxx | ||||
Case #009-03 | “Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase” U.S. Non-Provisional/Regular Patent Application 10/780,150 Inventors: X. Xxxx and X. Xxxxxx | ||||
Case #009-03 | “Use of Inhibitors of Indoleamine-2,3-Dioxygenase in Combination with Other Therapeutic Modalities” U.S. Non-Provisional/Regular Patent Application 10/780,797 Inventors: X. Xxxx and X. Xxxxxx] |